Elligo Health Research Raises $20M to Connect More Physicians and Their Patients to Clinical Research as a Care Option

AUSTIN, Texas–(BUSINESS WIRE)–Elligo
Health Research, an integrated research organization (IRO),
announced today $20 million in Series C funding led by Piper
Jaffray Merchant Banking, a division of Piper Jaffray, with
participation from all lead Series A and B investors. This funding is
the second investment the company has gained in a little over a year for
its innovative and successful approach. In March 2018, Elligo announced $16
million in Series B funding.

“We believe in Elligo’s mission to help all patients have the best
access to clinical trials as a care option,” said Tom
Schnettler, managing director at Piper Jaffray Merchant Banking and
a new Elligo board member. “With more than 62 active research sites,
their model has proven itself as the ultimate solution for enhanced
patient access and engagement, and that is something we are excited to
support.”

“The goal is to drive clinical trial efficiency through innovation,”
said John
Potthoff, PhD, CEO of Elligo. “Our investors’ continued support in
our unique Goes
Direct® approach and novel IntElligo Research Stack™ clinical
technology has allowed us to quickly expand the base of physicians and
their patients who otherwise would not participate in clinical trials.”

“We are proud to renew our investment in Elligo,” said John
Crumpler, general partner at Hatteras
Venture Partners. “Accelerating the development of new
pharmaceutical, biotechnology, medical device, and diagnostic products
is paramount in improving global health.”

“Elligo’s vision to positively impact future generations is something
we’re excited to continue to support,” said Allen
Moseley, managing general partner at Noro-Moseley
Partners.

About Elligo
Elligo
Health Research, an integrated research organization (IRO),
accelerates the development of new pharmaceutical, biotechnology,
medical device, and diagnostic products using our novel IntElligo
Research Stack™ clinical technology and our Goes Direct® approach. We
unite the best clinical experts with the best research infrastructure —
creating the ultimate clinical trial solution. It is our mission to
ensure that all patients have access to clinical trials as a care option
by maintaining the integrity of the trusted patient and physician
relationship, and building global communities of research leveraging
electronic health records. In doing so, we expand the base of physicians
and their patients who otherwise would not participate in clinical
trials. Learn more at elligodirect.com.

About Piper Jaffray
Piper Jaffray Companies (NYSE: PJC) is a
leading investment bank and asset management firm. Securities brokerage
and investment banking services are offered in the U.S. through Piper
Jaffray & Co., member SIPC
and FINRA;
in Europe through Piper Jaffray Ltd., authorized and regulated by the
U.K. Financial Conduct Authority; and in Hong Kong through Piper Jaffray
Hong Kong Limited, authorized and regulated by the Securities and
Futures Commission. Asset management products and services are offered
through five separate investment advisory affiliates―U.S. Securities and
Exchange Commission (SEC) registered Advisory Research, Inc., Piper
Jaffray Investment Management LLC, PJC Capital Partners LLC and Piper
Jaffray & Co., and Guernsey-based Parallel General Partners Limited,
authorized and regulated by the Guernsey Financial Services Commission.

Contacts

Jane Byram
SCORR Marketing
512.626.2758
[email protected]